Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Maintains Outperform on Kala Bio, Raises Price Target to $33

Author: Benzinga Newsdesk | September 11, 2025 08:29am
Oppenheimer analyst Andreas Argyrides maintains Kala Bio (NASDAQ:KALA) with a Outperform and raises the price target from $15 to $33.

Posted In: KALA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist